Personalis (NASDAQ:PSNL) CEO Sells $219,397.18 in Stock

Personalis, Inc. (NASDAQ:PSNL) CEO Christopher Hall sold 19,909 shares of the business’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $11.02, for a total value of $219,397.18. Following the sale, the chief executive officer owned 235,986 shares of the company’s stock, valued at $2,600,565.72. The trade was a 7.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Personalis Price Performance

NASDAQ PSNL traded up $0.42 on Friday, reaching $11.40. The company had a trading volume of 4,471,474 shares, compared to its average volume of 2,505,722. The firm has a market capitalization of $1.19 billion, a PE ratio of -11.18 and a beta of 1.96. Personalis, Inc. has a 1 year low of $3.84 and a 1 year high of $11.85. The firm has a 50-day moving average of $6.86 and a 200-day moving average of $8.10.

Personalis (NASDAQ:PSNL) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). The company had revenue of $15.47 million during the quarter, compared to analysts’ expectations of $14.49 million. Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%. As a group, sell-side analysts expect that Personalis, Inc. will post -1.06 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on PSNL shares. Wall Street Zen cut Personalis from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. Morgan Stanley decreased their price target on Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. Needham & Company LLC upped their price target on Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Finally, BTIG Research cut their target price on Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Monday, May 11th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

Institutional Investors Weigh In On Personalis

Several institutional investors and hedge funds have recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. raised its position in shares of Personalis by 273.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock valued at $85,812,000 after acquiring an additional 7,896,714 shares in the last quarter. ARK Investment Management LLC raised its position in shares of Personalis by 11.3% during the 3rd quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock valued at $51,574,000 after acquiring an additional 802,268 shares in the last quarter. Aberdeen Group plc raised its position in shares of Personalis by 36.1% during the 4th quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock valued at $25,869,000 after acquiring an additional 861,948 shares in the last quarter. Kennedy Capital Management LLC raised its position in shares of Personalis by 196.2% during the 3rd quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock valued at $12,617,000 after acquiring an additional 1,281,695 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Personalis by 1,332.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,448,585 shares of the company’s stock valued at $11,531,000 after acquiring an additional 1,347,439 shares in the last quarter. 61.91% of the stock is owned by institutional investors and hedge funds.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.